Literature DB >> 7514063

Distribution of C3-step regulatory proteins of the complement system, CD35 (CR1), CD46 (MCP), and CD55 (DAF), in hematological malignancies.

T Seya1, M Matsumoto, T Hara, M Hatanaka, T Masaoka, H Akedo.   

Abstract

The distribution and levels of three membrane proteins, CD35, CD46, and CD55, which serve as complement regulators, were examined in normal peripheral blood and hematologically malignant cells. CD35 was negative in most leukemia cells regardless of the type of leukemia, although granulocytes, monocytes, and some populations of lymphocytes were CD35+. CD46 was present in all blood cells except erythrocytes, and levels were 2-8 times higher in most leukemia cells than in their mature counterparts, particularly in CML and CLL cells, except for those of B cell lineage. CD55, a widely-distributed phosphatidyl inositol-anchored protein, was more frequently lost in NHL cells than in other types of hematological malignancies. In this review, we discuss the roles, mechanisms, and clinical applications of cell-associated complement regulatory proteins in hematological malignancies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514063     DOI: 10.3109/10428199409073780

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

1.  Detection of CD55- and/or CD59-deficient red cell populations in patients with plasma cell dyscrasias.

Authors:  John Meletis; Evangelos Terpos; Michalis Samarkos; Christos Meletis; Effie Apostolidou; Veroniki Komninaka; Konstantinos Korovesis; Konstantinos Anargyrou; Olga Benopoulou; Despina Mavrogianni; Eleni Variami; Nora Viniou; Konstantinos Konstantopoulos
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

2.  Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg.

Authors:  David D Kim; Takashi Miwa; Yuko Kimura; Reto A Schwendener; Menno van Lookeren Campagne; Wen-Chao Song
Journal:  Blood       Date:  2008-06-04       Impact factor: 22.113

Review 3.  Gene and virotherapy for hematological malignancies.

Authors:  Evidio Domingo-Musibay; Masato Yamamoto
Journal:  Int J Hematol       Date:  2016-06-11       Impact factor: 2.490

4.  Expression of membrane cofactor protein (MCP, CD46) in human liver diseases.

Authors:  N Kinugasa; T Higashi; K Nouso; H Nakatsukasa; Y Kobayashi; M Ishizaki; N Toshikuni; K Yoshida; S Uematsu; T Tsuji
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

Review 5.  Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.

Authors:  Saskia Meyer; Jeanette H W Leusen; Peter Boross
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

6.  Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas.

Authors:  Massimo Fantini; Justin M David; Olga Saric; Alexander Dubeykovskiy; Yongzhi Cui; Sharon A Mavroukakis; Andrew Bristol; Christina M Annunziata; Kwong Y Tsang; Philip M Arlen
Journal:  Front Immunol       Date:  2018-01-04       Impact factor: 7.561

Review 7.  The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy.

Authors:  Anne Geller; Jun Yan
Journal:  Front Immunol       Date:  2019-05-21       Impact factor: 7.561

8.  Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.

Authors:  A Dispenzieri; C Tong; B LaPlant; M Q Lacy; K Laumann; D Dingli; Y Zhou; M J Federspiel; M A Gertz; S Hayman; F Buadi; M O'Connor; V J Lowe; K-W Peng; S J Russell
Journal:  Leukemia       Date:  2017-04-25       Impact factor: 11.528

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.